文献速递泌尿男性生殖肿瘤

剂量递增局灶挽救高剂量率近距离放疗与基因组分类器风险分层治疗放射性复发前列腺癌:F-SHARP I/II期临床试验

Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial.
PubMed 文献 · J Clin Oncol · 2026-10-14

F-SHARP是一项多机构I/II期试验,评估剂量递增局灶挽救高剂量率近距离放疗(DE-fsHDR)治疗根治性放疗后前列腺内放射性复发(IPR)的安全性和有效性,并探索基因组分类器(GC)的风险分层作用。62例患者接受最多30 Gy分1-2次照射,中位随访39.4个月,未发生急性3级毒性,3年bPFS为62.7%;GC评分较高与更差的生存结局相关。

要点

  • DE-fsHDR治疗IPR安全,无急性3级毒性,仅2例(3.2%)晚期3级毒性。
  • 3年bPFS 62.7%、rPFS 67.5%、LRFS 73.0%、MFS 85.9%,分次方案间无差异。
  • GC评分>0.85的患者(n=4)均出现生化、局部和转移复发。

核心结论

  • DE-fsHDR是IPR安全有效的挽救治疗。
  • GC评分是接受挽救局部治疗的IPR患者有前景的预后工具,需进一步研究指导治疗强化。

研究设计与样本

  • 多机构I/II期临床试验(F-SHARP),纳入根治性放疗后前列腺内放射性复发的患者。
  • 主要终点为急性放疗相关≥3级CTCAE v4.03泌尿生殖和胃肠道毒性率。

主要发现

  • 中位随访39.4个月,无急性3级毒性发生,2例(3.2%)出现晚期3级毒性。
  • 生活质量变化未达到最小临床重要差异标准。
  • 3年bPFS 62.7%、rPFS 67.5%、LRFS 73.0%、MFS 85.9%,分次组间无差异(所有P > .05)。
  • 31例有GC结果的患者中,较高评分与更差的bPFS、rPFS、LRFS和MFS相关。
  • GC评分>0.85的患者(n=4)均出现生化、局部和转移复发。

临床怎么用

  • DE-fsHDR可作为IPR的挽救治疗选择,安全性可接受。
  • GC评分可用于风险分层,高分患者可能需考虑治疗强化。

局限性

  • GC分析仅31例患者,样本量有限。
  • GC评分>0.85的患者仅4例,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. METHODS: F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS). RESULTS: Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence. CONCLUSION: DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Solanki AA, Adams W, Proudfoot JA, et al. Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial. J Clin Oncol. 2026. PMID: 42874014. doi:10.1200/JCO-25-02730

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。